BMS and NVIDIA Build Pharma’s AI Supercomputer
BMS and NVIDIA are building a powerful pharma AI factory using advanced supercomputing, AI models, and scientific data to accelerate drug discovery.
Articles, expert interviews, and insights from life sciences leaders
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
FDA Oncology Trial Guidance Targets Eligibility Barriers
FDA oncology clinical trial guidance targets restrictive eligibility criteria, covering performance status, washout periods, medications, and laboratory values.
EHR Patient Recruitment Gets A Reality Check
EHR patient recruitment could improve clinical trial matching, but workflow integration, data quality, interoperability, and AI validation remain key challenges.
Throne Science: Passive Health Monitoring in the Bathroom
Read about how Throne Science is advancing passive health monitoring with AI-powered sensing that automatically captures daily toilet habit data.
How Should Pharma Companies Audit AI Vendors?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
FDA Generic Peptides Guidance Sets New Expectations
Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.
The Ethics of Decentralised Clinical Trials
Ethical obligations in decentralised clinical trials extend beyond consent and privacy. Sponsors must protect safety, scientific validity, equity, and oversight.
AI Creates New Viruses? Not Quite. AI-Designed Bacteriophages
AI-designed bacteriophages show how genome models could create new antibacterial therapies while forcing pharma to rethink biological AI governance and biosecurity.
WHOOP x Natural Cycles: Wearable Health Data x Women’s Health
WHOOP and Natural Cycles show how wearable health data is moving into regulated digital health, creating new opportunities for women’s health and pharma.
Making Flexibility Work with Adaptive Clinical Trials
Adaptive clinical trials can improve efficiency, reduce patient burden, and support faster development through structured, evidence-based flexibility.
RNA Biosensors for Real-Time Diabetes Detection and Monitoring
RNA biosensors for diabetes could allow earlier diagnosis and better personalised care. Explore the power of AI monitoring and next-generation molecular diagnostics.
AI in GMP Manufacturing: Are Regulators Ready for Digital Factories?
Learn how AI in pharmaceutical GMP manufacturing is improving quality, data integrity, predictive maintenance, and regulatory compliance in modern drug production.
